Results 181 to 190 of about 44,633 (211)

Rate of Progression of Transthyretin Amyloidosis

The American Journal of Cardiology, 2011
Hereditary transthyretin (TTR) amyloidosis is an adult-onset disease characterized mainly by peripheral neuropathy and cardiomyopathy. Although disease progression is usually 5 to 15 years from time of diagnosis to death, no specific measurements of disease progression have been identified.
Merrill D, Benson, Shawn D, Teague, Richard, Kovacs, Harvey, Feigenbaum, Jeesun, Jung, John C, Kincaid   +5 more
openaire   +2 more sources

Expanding the spectrum of transthyretin amyloidosis

Muscle & Nerve, 2019
See article on pages 95–100 in this issue.
Haruki Koike, Masahisa Katsuno
openaire   +2 more sources

Laboratory Assessment of Transthyretin Amyloidosis

Clinical Chemistry and Laboratory Medicine, 2002
Mutations in transthyretin (TTR) are the most common cause of autosomal dominant systemic amyloidosis. To date, more than 80 TTR mutations have been associated with amyloidosis in humans. A high prevalence of some mutations like Val122Ile which is identified in 3% of African Americans indicates the necessity of thorough investigation of patients ...
Merrill D, Benson, Masahide, Yazaki, Nadine, Magy   +2 more
openaire   +2 more sources

Vutrisiran for Transthyretin Amyloidosis Cardiomyopathy

Current Vascular Pharmacology

Angelica Lehker, Debabrata Mukherjee
openaire   +2 more sources

Investigation into thiol conjugation of transthyretin in hereditary transthyretin amyloidosis

European Journal of Clinical Investigation, 1998
BackgroundFor all forms of amyloidosis, the amyloid‐generating mechanism is unknown. Familial amyloidotic polyneuropathy type I is caused by a variant transthyretin (TTR Met‐30). As electrospray ionization mass spectrometry (ESI‐MS) discloses both thiol‐conjugated and ‐unconjugated forms of wild‐type and variant TTR, we wanted to investigate the ...
O B, Suhr, Y, Ando, P I, Ohlsson, A, Olofsson, K, Andersson, E, Lundgren, M, Ando, G, Holmgren   +7 more
openaire   +2 more sources

Hereditary transthyretin amyloidosis associated with a transthyretin variant Thr59Arg

Amyloid, 2017
Hereditary transthyretin (TTR) amyloidosis is characterized by ATTR amyloid deposits in various tissue sites and organs, such as peripheral nerves, heart, gastrointestinal tract, kidneys, eyes, and...
Tetsuya, Watanabe, Konen, Obayashi, Yohei, Misumi, Masayoshi, Tasaki, Satoru, Shinriki, Tomotaka, Ando, Takafumi, Akagami, Mitsuharu, Ueda, Taro, Yamashita, Shinichi, Hirotani, Yukio, Ando   +10 more
openaire   +2 more sources

Hereditary Transthyretin Amyloidosis Polyneuropathy

Seminars in Neurology
AbstractIn the last decade, we have witnessed dramatic improvements in the diagnosis, workup, management, and monitoring of patients with hereditary transthyretin amyloidosis (ATTRv). Updated imaging techniques (e.g., 99mTc-PYP scan) are increasingly being used in place of tissue biopsies for confirmation of disease.
Taha, Qarni, Orly, Moshe-Lilie, Michelle C, Kaku, Chafic, Karam   +3 more
openaire   +2 more sources

Liver transplantation and transthyretin amyloidosis

Muscle & Nerve, 2012
AbstractLiver transplantation as a specific treatment of transthyretin amyloidosis was first performed in 1990. The rationale for this treatment was that removal of the source (liver) of the amyloid precursor protein (mutated transthyretin) would stop progression of the disease. Indeed, after orthotopic liver transplantation (OLT), mutant transthyretin
openaire   +2 more sources

Isolated transthyretin valvular amyloidosis

European Heart Journal, 2023
Yi-Tsang Fu, Ling Kuo, Wen-Chung Yu
openaire   +2 more sources

Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis

European Journal of Heart Failure, 2022
Nikolaos Ioakeimidis, Dimitris Tousoulis
exaly